Long-term Therapy for Herpes Retinitis in an Animal Model With High-Concentrated Liposome-Encapsulated HPMPC

Archives of Ophthalmology

Volumn 113, Issue 5, 1995, Pages 661-668

  Besen, Gilberto ^a   Flores Aguilar, Marisa ^a   Assil, Kerry K ^b   Kupperman, Baruch D ^a   Gangan, Pacifico ^a   Pursley, Michael ^a,b   Munguia, David ^a   Clercq, Erik ^c   Bergeron Lynn, Germaine ^a   Azen, Stanley P ^d   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Anheuser Busch Eye Institute at St Louis University   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; ENCAPSULATION; EYE TOXICITY; HERPES; HERPES SIMPLEX VIRUS 1; HISTOLOGY; HUMAN CYTOMEGALOVIRUS; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS;

ANIMAL; ANTIVIRAL AGENTS; CYTOSINE; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; EYE INFECTIONS, VIRAL; FUNDUS OCULI; HERPES SIMPLEX; LIPOSOMES; LONGITUDINAL STUDIES; ORGANOPHOSPHORUS COMPOUNDS; RABBITS; RETINITIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029020901     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.1995.01100050129042     Document Type: Article

References (38)

1. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
2. Palestine AG, Stevens G Jr, Lane HC, et al. Treatment of cytomegalovirus retinitis with dihyroxi-propoxymethyl guanine. Am J Ophthalmol. 1986;101:95-101.
3. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr. 1990;3:472-479.
4. Cantrill HL, Henry K, Melroe H, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology. 1989;96:367-374.
5. Heinemann MH. Long term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989;107:1767-1772.
6. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymetil guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987;103:17-23.
7. Ussery FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology. 1988;95:640-648.
8. Diaz-Llopis M, Chipont E, Sanchez S, Espana E, Navea A, Menezo JL. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;114:742-747.
9. Freeman WR. Intraocular antiviral therapy. Arch Ophthalmol. 1989;107:1737-1739.
10. Maurice DM. Use of intravitreal ganciclovir (propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987;103:842-844.
11. Daikos GL, Pulido J, Kathapalia SD, Jackson GG. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. Br J Ophthalmol. 1988;72:521-524.
12. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol. 1992;110:255-258.
13. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol. 1992;110:188-195.
14. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol. 1993;111:223-227.
15. Knox K, Drobyski W, Carrigan D. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a bone marrow transplant. Lancet. 1991;255:1292-1293.
16. De Clercq E, Sakuma T, Baba M, et al. Antivital activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res. 1987;8:261-272.
17. Shigeta S, Konno K, Baba M, Yokota T, De Clercq E. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J Infect Dis. 1991;63:270-275.
18. Li SB, Yang ZH, Feng JS, Fong CK, Lucia HL, Hsiung GD. Activity of (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 1990;13:237-252.
19. Neyts J, Snoeck R, Balzarini J, De Clercq E. Particular characteristics of the antihuman cytomegalovirus activity of (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) in vitro. Antiviral Res. 1991;16:41-52.
20. Snoeck S, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine: a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988;32:1839-1844.
21. Dolnak DR, Munguia D, Wiley CA, et al. Lack of retinal toxicity of the anti-CMV drug (s)-1-(3-hydroxy-2-phosphonylme-thoxypropyl) cytosine (HPMPC). Invest Ophthalmol Vis Sci. 1992;33:1557-1563.
22. Flores-Aguilar M, Huang J-S, Wiley CA, et al. Long acting therapy of viral retinitis with HPMPC. J Infect Dis. 1994;169:642-647.
23. Kimm S, Turker MS, Chi EY, Shifa S, Martin GM. Preparation of multivesicular liposomes. Biochim Biophys Acta. 1983;728:339-398.
24. Assil KK, Weinreb RN. Multivesicular liposomes: sustained release of the antimetabolite cytosine arabinoside in the eye. Arch Ophthalmol. 1987;105:400-405.
25. Freeman WR, Wiley CA, Assil KK, Gariano R, Listhaus A, Munguia D, Schneiderman T, Svendsen P. Experimental intravitreal drug delivery for retinal disease. In: Pharmacotherapy of the Eye. New York, NY: Springer-Verlag NY Inc; 1992:231-242.
26. Votruba I, Bernaerts R, Sakuma T, et al. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (s)-9-(3-hydroxy-2-phosphonyl-methoxypropyl) adenine and inhibition of viral DNA synthesis. Mol Pharmacol. 1987;32:524-529.
27. Flores-Aguilar M, Kupperman BD, Quiceno JI, et al. Pathophysiology and therapy of clinically resistant cytomegalovirus retinitis. Ophthalmology. 1993;100:1022-1031.
28. Gazzard BG. Foscarnet therapy in persons with AIDS: clinical research and management consultations. J Acquir Immune Defic Syndr. 1992;5(suppl 1):S1-S2.
29. Schulman J, Peyman GA, Horton MB, et al. Intraocular 9-([2-hydroxy-1-(hydroxymethyl)ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration. Ophthalmic Surg. 1986;17:429-432.
30. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immunodeficiency syndrome. Ophthalmology. 1991;98:1348-1355.
31. Buchi ER, Fiiting PL, Michel AE. Long-term intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS. Arch Ophthalmol. 1989;106:1349-1350.
32. Díaz-Llopis M, Martos J, España E, et al. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Doc Ophthalmol. 1992;82:297-305.
33. Yoshyzumi M, Lee D, Vinci V, Fajardo S. Ocular toxicity of multiple intravitreal DHPG injections. Graefes Arch Clin Exp Ophthalmol. 1990;228:350-355.
34. Neyts J, Snoeck R, Schols D, Balzarini J, De Clercq E. Selective inhibition of human cytomegalovirus DNA synthesis by (s)-1-(3-hydroxy-2 phosphonylmethoxypropyl) cytosine[(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). Virology. 1990;179:41-50.
35. Freeman WR, Wiley CA, Flores-Aguilar M, Bergeron-Lynn, G, Besen G. Animal models of herpes family viral retinitis. Antiviral Res. 1994;23(suppl 1):137.
36. von Szily A. An experimental endogenous transmission of infection from bulbus to bulbus. Klin Monatsbl Augenheilkd. 1924;75:593-602.
37. Freeman WR, Schneiderman T, Wiley CA, et al. An animal model of focal, subacute viral retinitis. Retina. 1993;13:214-221.
38. Bylsma SS, Achim CL, Wiley CA, et al. The predictitve value of cytomegalovirus retinitis for cytomegalovirus encephalitis in AIDS. Arch Ophthalmol. 1995;113:89-95.